⚡ Black Friday Offer: Click here and shop now!

TextRanch

The best way to perfect your writing.

Discover why 1,062,726 users count on TextRanch to get their English corrected!

1. Input your text below.
2. Get it corrected in a few minutes by our editors.
3. Improve your English!

One of our experts will correct your English.

Our experts

in the end of treatment vs at the end of treatment

Both phrases are correct, but they are used in different contexts. 'At the end of treatment' is the more common and appropriate choice when referring to the conclusion or completion of a treatment process. 'In the end of treatment' could be used in a more abstract or general sense, but it is less common.

Last updated: March 23, 2024 • 939 views

in the end of treatment

This phrase is correct but less common than 'at the end of treatment.'

This phrase can be used in a more abstract or general sense when referring to the conclusion of a treatment process.
  • All unused capsules should be returned to the pharmacist at the end of treatment.
  • Any remaining ointment at the end of treatment should be discarded.
  • Efficacy was defined as sustained virologic response, 6 months after the end of treatment.
  • This effect may become apparent only after the end of treatment with EMEND.
  • She understands the need and accepts to undergo pregnancy testing before, during and 5 weeks after the end of treatment.
  • Negative pregnancy test results have been obtained before, during and 5 weeks after the end of treatment.
  • Additional precautions Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment.
  • Negative pregnancy test results have been obtained before, during and 5 weeks after the end of treatment.
  • Six weeks after the end of treatment, five out of the nine separation anxiety behaviours were still improved in about a third of the treated dogs.
  • At the end of treatment it is not necessary to taper or reduce doses because of the long half life of this product.
  • Typically, these findings normalised, or appeared to be reversing, within two weeks following the end of treatment.
  • Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment.
  • Posaconazole was shown to be non-inferior to fluconazole for clinical success rates at Day 14 as well as 4 weeks after the end of treatment.
  • All patients were followed for an additional 6 months after the end of treatment for the determination of sustained virologic response.
  • From then on, the patient takes one 1 mg tablet twice daily until the end of treatment (12 weeks).
  • Evaluation of precipitation should be done by methods such as light microscopy, noting precipitate that persists, or appears during culture (by the end of treatment).
  • Follow-up and end of treatment A medically supervised pregnancy test should be repeated every 4 weeks, including 4 weeks after the end of treatment.
  • She understands the need and accepts to undergo pregnancy testing before, during and 5 weeks after the end of treatment.
  • any unused capsules to their pharmacist at the end of treatment.
  • In order to avoid this rebound weight gain, it is necessary to continue the feeding for maintenance regimen after the end of treatment with the product.

Alternatives:

  • at the end of treatment
  • when the treatment ends
  • after the treatment is completed
  • upon completion of the treatment
  • following the treatment's conclusion

at the end of treatment

This phrase is the more common and appropriate choice when referring to the conclusion or completion of a treatment process.

This phrase is commonly used to specify the point when a treatment process concludes or is completed.
  • All unused capsules should be returned to the pharmacist at the end of treatment.
  • Any remaining ointment at the end of treatment should be discarded.
  • Additional precautions Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment.
  • Fesoterodine treated patients had statistically significant mean reductions in the number of micturitions per 24 hours and in the number of urge incontinence episodes per 24 hours at the end of treatment compared to placebo.
  • any unused capsules to their pharmacist at the end of treatment.
  • Clinical trials, which have included gradual dose reduction at the end of treatment, have found that 30% of patients developed symptoms following discontinuation of treatment with paroxetine compared to 20% among those stopping placebo.
  • That she should return the capsules to the pharmacist at the end of treatment
  • As shown in Table 3, a successful response (complete or partial resolution) at the end of treatment was seen in 42% of posaconazole-treated patients compared to 26% of the external group.
  • Your doctor may decide to gradually lower your dose of CHAMPIX at the end of treatment.
  • In invasive aspergillosis, a successful response at the end of treatment was seen in 42% of the patients taking Posaconazole SP, compared with 26% of the comparison group.
  • In invasive aspergillosis, a successful response at the end of treatment was seen in 42% of the patients taking Noxafil, compared with 26% of the comparison group.
  • 11 of 16 patients were successfully treated (at the end of treatment complete or partial resolution of signs and symptoms present at baseline) with posaconazole 800 mg/ day in divided doses for a median of 296 days and up to 460 days.
  • The main measure of effectiveness was the proportion of patients who were cured at the end of treatment as determined by a reduction in symptoms, or who had' satisfactory' reductions in the amount of bacteria detected in samples.
  • Cells are sampled at a time equivalent to about 1,5-2,0 times the normal (i.e. untreated) cell cycle length either after the beginning or at the end of treatment (See Table 1).
  • Rebetol is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.
  • In all three studies, the main measure of effectiveness was the number of patients in whom treatment was successful, based on an improvement in symptoms and eradication of the fungus at the end of treatment.
  • At the end of treatment it is not necessary to taper or reduce doses because of the long half life of this product.
  • At the end of treatment (over 6 or 8 weeks), significant efficacy of agomelatine 25-50 mg was demonstrated in 3 of the six short-term double-blind placebo-controlled studies.
  • Relapse of Virological Response at the End of Treatment for Rapid Virological Response Population
  • At the end of treatment, discontinuation of CHAMPIX was associated with an increase in irritability, urge to smoke, depression, and/ or insomnia in up to 3% of patients.

Alternatives:

  • in the end of treatment
  • when the treatment ends
  • after the treatment is completed
  • upon completion of the treatment
  • following the treatment's conclusion

Related Comparisons

What Our Customers Are Saying

Our customers love us! We have an average rating of 4.79 stars based on 283,125 votes.
Also check out our 2,100+ reviews on TrustPilot (4.9TextRanch on TrustPilot).

Why choose TextRanch?

Lowest prices
Up to 50% lower than other online editing sites.

Fastest Times
Our team of editors is working for you 24/7.

Qualified Editors
Native English experts for UK or US English.

Top Customer Service
We are here to help. Satisfaction guaranteed!

×

⚡️ Black Friday 2024 ⚡️

Stock up on credits for the entire year!

Grab this offer now!